Immunotherapy | CHOP Research Institute
 

Immunotherapy

Dr. Wolpaw’s laboratory seeks to develop an understanding of how tumor heterogeneity and epigenetics impact inflammatory signaling and immunotherapy responses in pediatric solid tumors with a goal of developing more efficacious, less toxic therapies to treat these devastating diseases.

Published on
Dec 29, 2022
These six Cornerstone stories garnered the most engagements from our CHOP Research Twitter, Facebook, and LinkedIn channels.
Published on
Nov 30, 2022
The Emerging Innovators at CHOP Research Institute cover a variety of scientific disciplines.
Published on
Nov 11, 2022
This week’s research news roundup includes accolades for our scientists and the spaces they work in.
Published on
Jun 24, 2022
This week’s In the News features endocrinology research, news on gene therapy in blood disorders, CAR T-cell therapy, and more.
Published on
Feb 4, 2022
Learn about novel findings neuroblastoma, MIS-C, and more in this week's roundup of research news.
Published on
Feb 3, 2022
Two patients infused with CAR T-cell therapy one decade ago remain in remission with detectable levels of cancer-fighting cells.
Published on
Jan 3, 2022
Congratulations to Garrett Brodeur, MD, recipient of the American Society of Pediatric Hematology/Oncology Distinguished Career Award.
Published on
Dec 30, 2021
Here’s our list of the 2021 Cornerstone stories our social media followers engaged with the most.
Published on
Nov 3, 2021
The peptide-centric CAR T cells, or PC-CARS, target cancer drivers in tumor cells previously thought unreachable.